Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.

Richter-Pechańska P, Kunz JB, Bornhauser B, von Knebel Doeberitz C, Rausch T, Erarslan-Uysal B, Assenov Y, Frismantas V, Marovca B, Waszak SM, Zimmermann M, Seemann J, Happich M, Stanulla M, Schrappe M, Cario G, Escherich G, Bakharevich K, Kirschner-Schwabe R, Eckert C, Muckenthaler MU, Korbel JO, Bourquin JP, Kulozik AE.

EMBO Mol Med. 2018 Nov 2. pii: e9443. doi: 10.15252/emmm.201809443. [Epub ahead of print]

2.

Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.

Belger M, Haro JM, Reed C, Happich M, Argimon JM, Bruno G, Dodel R, Jones RW, Vellas B, Wimo A.

Eur J Health Econ. 2018 Sep 3. doi: 10.1007/s10198-018-1001-3. [Epub ahead of print]

PMID:
30178148
3.

Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal.

Makady A, Stegenga H, Ciaglia A, Debray TP, Lees M, Happich M, Ryll B, Abrams K, Thwaites R, Garner S, Jonsson P, Goettsch W.

J Comp Eff Res. 2017 Sep;6(6):485-490. doi: 10.2217/cer-2017-0044. Epub 2017 Aug 31.

4.

What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.

Reed C, Happich M, Argimon JM, Haro JM, Wimo A, Bruno G, Dodel R, Jones RW, Vellas B, Belger M.

J Alzheimers Dis. 2017;57(3):797-812. doi: 10.3233/JAD-160449.

PMID:
28304285
5.

Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.

Hornberger J, Bae J, Watson I, Johnston J, Happich M.

Curr Med Res Opin. 2017 Apr;33(4):675-685. doi: 10.1080/03007995.2016.1277197. Epub 2017 Jan 24.

PMID:
28035842
6.

Newborn screening for severe combined immunodeficiency using a novel and simplified method to measure T-cell excision circles (TREC).

Tagliaferri L, Kunz JB, Happich M, Esposito S, Bruckner T, Hübschmann D, Okun JG, Hoffmann GF, Schulz A, Kappe J, Speckmann C, Muckenthaler MU, Kulozik AE.

Clin Immunol. 2017 Feb;175:51-55. doi: 10.1016/j.clim.2016.11.016. Epub 2016 Dec 2.

PMID:
27916705
7.

How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.

Belger M, Haro JM, Reed C, Happich M, Kahle-Wrobleski K, Argimon JM, Bruno G, Dodel R, Jones RW, Vellas B, Wimo A.

BMC Med Res Methodol. 2016 Jul 18;16:83. doi: 10.1186/s12874-016-0188-1.

8.

Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.

Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.

J Alzheimers Dis. 2016 May 6;53(1):171-83. doi: 10.3233/JAD-150685.

9.

Newborn Screening for Sickle Cell Disease: Jamaican Experience.

Mason K, Gibson F, Gardner R, Warren L, Fisher C, Higgs D, Happich M, Kulozik A, Hambleton I, Serjeant BE, Serjeant GR.

West Indian Med J. 2015 Sep 22;65(1):18-26. doi: 10.7727/wimj.2015.492.

PMID:
26901597
10.

Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease.

Mühlbacher A, Johnson FR, Yang JC, Happich M, Belger M.

Value Health. 2016 Jan;19(1):66-74. doi: 10.1016/j.jval.2015.10.011. Epub 2016 Jan 12.

11.

Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.

Kunz JB, Awad S, Happich M, Muckenthaler L, Lindner M, Gramer G, Okun JG, Hoffmann GF, Bruckner T, Muckenthaler MU, Kulozik AE.

Ann Hematol. 2016 Feb;95(3):397-402. doi: 10.1007/s00277-015-2573-y. Epub 2015 Dec 12.

PMID:
26658910
12.

Excess Costs Associated With Possible Misdiagnosis of Alzheimer's Disease Among Patients With Vascular Dementia In Italy.

Barrett A, Belger M, Dell'Agnello G, Mancini M, Reed C, Sangiori D, Blini V, Buda S, Esposti LD, Happich M.

Value Health. 2015 Nov;18(7):A753. doi: 10.1016/j.jval.2015.09.2918. Epub 2015 Oct 20. No abstract available.

13.

Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.

Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T, Happich M.

J Ment Health Policy Econ. 2015 Jun;18(2):63-73.

PMID:
26231002
14.

Haemoglobin Variant Screening in Jamaica: Meeting Student's Request.

Mason K, Gibson F, Higgs D, Fisher C, Thein SL, Clark B, Kulozik A, Happich M, Serjeant B, Serjeant G.

Br J Haematol. 2016 Feb;172(4):634-6. doi: 10.1111/bjh.13531. Epub 2015 Jun 30. No abstract available.

PMID:
26123225
15.

Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.

Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA.

Pediatr Pulmonol. 2015 Jul;50(7):655-64. doi: 10.1002/ppul.23190. Epub 2015 Apr 23.

PMID:
25914230
16.

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.

Dodel R, Belger M, Reed C, Wimo A, Jones RW, Happich M, Argimon JM, Bruno G, Vellas B, Haro JM.

Alzheimers Dement. 2015 Aug;11(8):933-45. doi: 10.1016/j.jalz.2015.02.005. Epub 2015 Apr 4.

PMID:
25846298
17.

Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.

Barros BR, Schacht A, Happich M, Televantou F, Berggren L, Walker DJ, Dueñas HJ.

Prim Care Companion CNS Disord. 2014 Oct 2;16(5). doi: 10.4088/PCC.14m01661. eCollection 2014.

18.

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.

Dilla T, Möller J, O'Donohoe P, Álvarez M, Sacristán JA, Happich M, Tockhorn A.

BMC Psychiatry. 2014 Dec 2;14:298. doi: 10.1186/s12888-014-0298-4.

19.

The Value of Diagnostic Tests for Alzheimer's Disease: Discrete-Choice Experiment and Contingent-Valuation.

Mühlbacher AC, Johnson FR, Yang JC, Happich M.

Value Health. 2014 Nov;17(7):A402. doi: 10.1016/j.jval.2014.08.922. Epub 2014 Oct 26. No abstract available.

20.
21.

Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.

Wielage RC, Patel AJ, Bansal M, Lee S, Klein RW, Happich M.

Arthritis Care Res (Hoboken). 2014 May;66(5):702-8.

PMID:
24877251
22.

Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer's disease and other dementia using autopsy as standard of truth.

Cure S, Abrams K, Belger M, Dell'agnello G, Happich M.

J Alzheimers Dis. 2014;42(1):169-82. doi: 10.3233/JAD-131559. Review.

PMID:
24840572
23.

The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.

Myers J, Wielage RC, Han B, Price K, Gahn J, Paget MA, Happich M.

BMC Musculoskelet Disord. 2014 Mar 11;15:76. doi: 10.1186/1471-2474-15-76. Review.

24.

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective-author response to letter to the editor.

Wielage RC, Bansal M, Scott Andrews J, Wohlreich MM, Klein RW, Happich M.

Value Health. 2013 Dec;16(8):1173-4. doi: 10.1016/j.jval.2013.09.005. No abstract available.

25.

Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.

Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, Ziegler D.

Clin J Pain. 2014 Oct;30(10):875-85. doi: 10.1097/AJP.0000000000000057.

PMID:
24296910
26.

Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.

Wielage RC, Myers JA, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Dec;11(6):593-618. doi: 10.1007/s40258-013-0061-x. Review.

PMID:
24214160
27.
28.

Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Oct;11(5):555-7. doi: 10.1007/s40258-013-0049-6. No abstract available.

PMID:
23907656
29.

Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.

Sommerburg O, Krulisova V, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Votava F, Balascakova M, Skalicka V, Stopsack M, Gahr M, Macek M Jr, Mall MA, Hoffmann GF.

J Cyst Fibros. 2014 Jan;13(1):15-23. doi: 10.1016/j.jcf.2013.06.003. Epub 2013 Jul 25.

30.

Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain.

Cawston H, Davie A, Paget MA, Skljarevski V, Happich M.

Eur Spine J. 2013 Sep;22(9):1996-2009. doi: 10.1007/s00586-013-2804-7. Epub 2013 May 18. Review.

31.

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.

Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, Argimon JM, Bruno G, Novick D, Vellas B, Haro JM.

J Alzheimers Dis. 2013;36(2):385-99. doi: 10.3233/JAD-122392.

PMID:
23629588
32.

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Jun;11(3):219-36. doi: 10.1007/s40258-013-0031-3.

PMID:
23616247
33.

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M.

Value Health. 2013 Mar-Apr;16(2):334-44. doi: 10.1016/j.jval.2012.12.006.

34.
35.

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Wielage R, Bansal M, Wilson K, Klein R, Happich M.

Spine (Phila Pa 1976). 2013 May 15;38(11):936-46. doi: 10.1097/BRS.0b013e31828264f9.

PMID:
23250234
36.

Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database.

Hong J, Reed C, Novick D, Happich M.

Spine (Phila Pa 1976). 2013 Jan 1;38(1):75-82. doi: 10.1097/BRS.0b013e318276450f.

PMID:
23038621
37.

Depression treatment with duloxetine and reduction of inability to work.

Happich M, Schneider E, Wilhelm S, Zimmermann T, Schacht A.

Depress Res Treat. 2012;2012:264854. doi: 10.1155/2012/264854. Epub 2012 Aug 2.

38.

Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom.

Shi N, Durden E, Torres A, Cao Z, Happich M.

Depress Res Treat. 2012;2012:815363. doi: 10.1155/2012/815363. Epub 2012 Jun 7.

39.

Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.

Shi N, Cao Z, Durden E, Schacht A, Torres A, Happich M.

J Med Econ. 2012;15(4):672-80. doi: 10.3111/13696998.2012.672941. Epub 2012 Mar 20.

PMID:
22390770
40.

Screening for the beta-thalassaemia trait: hazards among populations of West African Ancestry.

Gibson F, Mason K, Serjeant B, Kulozik A, Happich M, Tolle G, Hambleton I, Serjeant G.

J Community Genet. 2012 Jan;3(1):13-8. doi: 10.1007/s12687-011-0069-6. Epub 2011 Nov 3.

41.

Excess health care costs of obesity in adults with diabetes mellitus: a claims data analysis.

von Lengerke T, Hagenmeyer EG, Gothe H, Schiffhorst G, Happich M, Häussler B.

Exp Clin Endocrinol Diabetes. 2010 Aug;118(8):496-504. doi: 10.1055/s-0030-1253400. Epub 2010 May 21.

PMID:
20496315
42.

Health state valuation methods and reference points: the case of tinnitus.

Happich M, Moock J, von Lengerke T.

Value Health. 2009 Jan-Feb;12(1):88-95. doi: 10.1111/j.1524-4733.2008.00397.x.

43.

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.

Diabetes Obes Metab. 2009 Nov;11(11):1068-79. doi: 10.1111/j.1463-1326.2009.01099.x. Epub 2009 Sep 3.

PMID:
19732121
44.

Longitudinal change in HbA1c in patients with type 2 diabetes: comparison of short-acting, biphasic and basal insulin.

Rathmann W, Strassburger K, Kostev K, Schröder-Bernhardi D, Giani G, Happich M.

Exp Clin Endocrinol Diabetes. 2009 May;117(5):230-3. doi: 10.1055/s-0028-1128125. Epub 2009 Feb 18.

PMID:
19226479
45.

The effect of insulin lispro on glycemic control in a large patient cohort.

Lind M, Fahlén M, Happich M, Odén A, Eliasson B.

Diabetes Technol Ther. 2009 Jan;11(1):51-6. doi: 10.1089/dia.2007.0297.

PMID:
19132856
46.

Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study.

Meisinger C, Heier M, Landgraf R, Happich M, Wichmann HE, Piehlmeier W.

BMC Health Serv Res. 2008 Nov 5;8:226. doi: 10.1186/1472-6963-8-226.

47.

Diabetic retinopathy and health-related quality of life.

Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M.

Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):267-72. doi: 10.1007/s00417-008-0960-y. Epub 2008 Oct 17.

PMID:
18925408
48.

[Overall burden to society caused by hyperkinetic syndrome (HKS) and attention deficit hyperactivity disorder (ADHD)].

Schöffski O, Sohn S, Happich M.

Gesundheitswesen. 2008 Jul;70(7):398-403. doi: 10.1055/s-0028-1082049. Review. German.

PMID:
18729028
49.

Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study.

Liebl A, Breitscheidel L, Nicolay C, Happich M.

Curr Med Res Opin. 2008 Aug;24(8):2349-58. doi: 10.1185/03007990802292728. Epub 2008 Jul 4.

PMID:
18606055
50.

The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002--results from the Diabetic Microvascular Complications (DIMICO) study.

Happich M, John J, Stamenitis S, Clouth J, Polnau D.

Diabetes Res Clin Pract. 2008 Aug;81(2):223-30. doi: 10.1016/j.diabres.2008.03.019. Epub 2008 Jul 7.

PMID:
18602714

Supplemental Content

Loading ...
Support Center